Get startedLog in
    Picture of ExpreS2ion Biotech Holding AB logo

    EXPRS2 — ExpreS2ion Biotech Holding AB News Story

    0.000.00%
    se flag iconLast trade - 00:00
    HealthcareHighly SpeculativeMicro CapSucker Stock
    All News

    Brief: Expres2ion Updates ES2B-C001 Phase I Programme and Reports Additional Preliminary Immunogenicity and Safety Observations

    Picture of ExpreS2ion Biotech Holding AB logoExpreS2ion Biotech Holding AB
    19/05/2026 13:10
    May 19 (Reuters) - ExpreS2ion Biotech Holding AB EXPRS2.ST:

PRELIMINARY PHASE I DATA SHOW ANTI-HER2 ANTIBODY RESPONSE IN ALL PATIENTS, NO SAFETY SIGNALS

REVISED PHASE II DESIGN IS MORE TARGETED, FOCUSED THAN PREVIOUSLY PLANNED, IS EXPECTED TO BE MORE CAPITAL-EFFICIENT

UPDATES ES2B-C001 PHASE I PROGRAMME

Source text: ID:nMFN1NSyHp

Further company coverage: EXPRS2.ST

 (Gdansk Newsroom)

 ((gdansk.newsroom@thomsonreuters.com;  +48 58 769 66 00;))

    Recent news on ExpreS2ion Biotech Holding AB

    See all news